Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Shannon R. Morris"'
Autor:
Rajesh K. Malik, Yili Pritchett, Jennifer Johnson, Balazs Medgyasszay, Shannon R. Morris, Renata Ferrarotto, Trevor M. Feinstein, William Jeffery Edenfield, Maria Rosario García-Campelo, Ian Anderson, Tibor Csőszi, Alfredo Sanchez-Hernandez, Sujith Kalmadi, Philip E. Lammers
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 17, Pp 5748-5756 (2021)
Cancer Medicine, Vol 10, Iss 17, Pp 5748-5756 (2021)
Background Supportive care interventions used to manage chemotherapy‐induced myelosuppression (CIM), including granulocyte colony‐stimulating factors (G‐CSFs), erythropoiesis‐stimulating agents (ESAs), and red blood cell (RBC) transfusions, a
Autor:
Maen A. Hussein, Raid Aljumaily, Shannon R. Morris, Bojan Zaric, Wahid Hanna, Didier Verhoeven, Z. Andric, Jie Xiao, J. Thaddeus Beck, Janakiraman Subramanian, Renata Ferrarotto, Joyce M Antal, Davorin Radosavljevic, Lowell L. Hart, Taofeek K. Owonikoko
Publikováno v:
Advances in therapy
Advances in Therapy
Advances in Therapy
Introduction Multilineage myelosuppression is an acute toxicity of cytotoxic chemotherapy, resulting in serious complications and dose modifications. Current therapies are lineage specific and administered after chemotherapy damage has occurred. Tril
Autor:
Rajesh K. Malik, Petros Nikolinakos, Ralph V. Boccia, Konstantin H. Dragnev, Shannon R. Morris, Robert Hoyer, Donald A. Richards, Taofeek K. Owonikoko, A. Lowczak, Patrick J. Roberts, Vi Kien Chiu, J.T. Beck, Tibor Csoszi, Raid Aljumaily, Lowell L. Hart, I. Bulat, Maen A. Hussein, P. Sawrycki, Jessica A. Sorrentino, M. Maglakelidze, C.M. Rocha Lima, S. Adler, Jared Weiss, Zhao Yang, Joyce M Antal, S.R. Schuster, Wahid Hanna, M. Domine Gomez, Anne Y. Lai, John T. Hamm
Publikováno v:
Annals of Oncology
Background Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intravenous CDK4/6 inhibitor in development to proactively preserve HSPC and immune system function duri
Autor:
Yili Pritchett, Maen A. Hussein, Rajesh K. Malik, I. Sinielnikov, G. Kuusk, T.A. Gersten, R. Agajanian, Antonio Calles, Shannon R. Morris, S. Gurubhagavatula, E. Thara, K. Lerro, M. Maglakelidze, O. Vynnychenko, Alexander I. Spira
Publikováno v:
Journal of Thoracic Oncology. 16:S33-S34
Autor:
Shannon R. Morris, Lori Mixson, Andrea Kelly, Matthew I. Milowsky, Elizabeth M. Woodson, Melissa J. Polasek, Brant A. Inman, Raj S. Pruthi, Garrett Nichols, Arjun Vasant Balar, Kristin Orr
Publikováno v:
Cancer Research. 81:CT242-CT242
Background: The recombinant poliovirus (PV):rhinovirus chimera, PVSRIPO, is a novel non-neurovirulent, intratumoral (IT) immunotherapy showing promising clinical activity in patients (pts) with recurrent glioblastoma and advanced anti-PD-1 refractory
Autor:
Hyo S Han, Nikola Vasev, Lazar Popovic, Donald A. Richards, Antoinette R. Tan, Željko Vojnović, Joyce M Antal, Shannon R. Morris, Zhao Yang, Gail S. Wright, Timothy J. Pluard, Joyce O'Shaughnessy, Ling Ma, Anu Thummala, Sharon Wilks, Michael A. Danso, Dušan Milenković
Summary Background Trilaciclib is an intravenous cell-cycle inhibitor that transiently maintains immune cells and haemopoietic stem and progenitor cells in G1 arrest. By protecting the immune cells and bone marrow from chemotherapy-induced damage, tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf5478aee18ddf1835eb8bca5197497d
https://doi.org/10.1016/s1470-2045(19)30616-3
https://doi.org/10.1016/s1470-2045(19)30616-3
Autor:
Igor Bondarenko, Davey B. Daniel, Lowell L. Hart, I. Kudaba, A. Dasgupta, Zhao Yang, K.D. Koynov, O. Ivashchuk, David R. Spigel, Jana Jaal, Joyce M Antal, Shannon R. Morris, Steven G Wolfe, A. Matitashvili, Rajesh K. Malik, V. Kuchava, T. Melkadze, J. Goldschmidt, Sreekanth Reddy
Publikováno v:
Annals of Oncology. 30:v713
Background Chemotherapy (chemo)-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Current supportive therapies are lineage specific and administered after damage has occurred. T, a highly selectiv
Autor:
Joyce M. Antal, Jennifer L. Gauvin, Carol Aghajanian, Jennifer J. Wheler, Ademi Santiago-Walker, Carla Kurkjian, Joanna Opalinska, Lillian L. Siu, Shubham Pant, Howard A. Burris, Shannon R. Morris, David S. Hong, Lee Ann Stayner, Jeffrey R. Infante, Katherine M. Bell-McGuinn
Publikováno v:
Investigational new drugs. 36(6)
BACKGROUND: We sought to determine the recommended phase II dose (RP2D) and schedule of GSK2141795, an oral pan-AKT kinase inhibitor. PATIENTS AND METHODS: Patients with solid tumors were enrolled in the dose-escalation phase. Pharmacokinetic (PK) an
Autor:
Kenneth L. McClain, Eric D. Jacobsen, Mark L. Heaney, James A. Whitlock, Carlos Rodriguez-Galindo, Cornfeld Mark J, Carl E. Allen, Robert B. Noble, Sarah R. Vaiselbuh, Shannon R. Morris, Deborah A. Smith, Amy A. Murnane, Robert J. Arceci, Robert Vassallo, Beth Ann Reedy, Alison Portnoy, Ira J. Dunkel
Publikováno v:
Pediatric bloodcancer. 64(5)
Background Langerhans cell histiocytosis (LCH) is a clonal neoplasm characterized by widely varied clinical presentations, including multisystem involvement and systemic inflammatory symptoms. The AKT pathway is relevant to survival and proliferation
Autor:
Kathleen N. Moore, Shannon R. Morris, Brian M. Slomovitz, David Mauro, Barbara Burtness, Christine H. Chung, Matthew L. Anderson, Ezra E.W. Cohen
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts Approaches that target key HPV genes critical for cancer growth and metastasis may improve survival for individuals diagnosed with carcinomas of the uterine cervix or head and neck. ADXS11-001 is a live attenuated Listeria monocytog